摘要
目的观察生长抑素联合美沙拉嗪对溃疡性结肠炎(UC)患者细胞免疫、炎性因子、超氧化物歧化酶(SOD)、丙二醛(MDA)的影响。方法将126例UC患者随机分为对照组和试验组,各63例。对照组给予美沙拉嗪肠溶片,每次0.5 g,每天3次,口服;试验组在对照组的基础上给予生长抑素,用5%的葡萄糖溶液溶解之后,首先缓慢静脉注射250 mg,而后立即进行250 mg·h^-1的静脉给药。2组均连续治疗2周。比较2组患者治疗前后调节性T细胞(Tregs)水平、炎性因子水平、SOD、MDA水平和肠黏膜炎症程度。结果治疗后,试验组和对照组Tregs水平分别为(9.69±1.31)%,(6.89±1.23)%,血清肿瘤坏死因子-α(TNF-α)分别为(1.23±0.11),(1.98±0.24)ng·mL^-1,白细胞介素-6(IL-6)分别为(92.01±8.49),(116.09±11.24)ng·mL^-1,白细胞介素-8(IL-8)分别为(151.38±15.29),(219.63±18.17)ng·mL^-1,白细胞介素-10(IL^-10)分别为(71.18±9.64),(43.49±6.19)ng·mL^-1,SOD分别为(1.81±0.28),(1.31±0.21)U·mL^-1,MDA分别为(5.66±1.21),(6.81±1.41)nmol·mL^-1,差异均有统计学意义(均P<0.05)。治疗后,试验组Level 0患者比例高于对照组,LevelⅡ患者比例低于对照组(P<0.05)。试验组和对照组的药物不良反应发生率分别为7.94%,22.22%,差异有统计学意义(P<0.05)。结论生长抑素联合美沙拉嗪可以显著改善UC患者机体Tregs及炎性因子水平,控制肠黏膜炎症反应,降低氧化应激水平,改善肠道功能,具有良好的治疗效果。
Objective To explore the effects of somatostatin combined with mesalazine on cellular immunity,inflammatory factors,superoxide dismutase(SOD),malondialdehyde(MDA)in patients with ulcerative colitis(UC).Methods A total of 126 patients with UC were randomly divided into control group and treatment group,63 cases in each group.Control group was given mesalazine enteric-coated tablets 0.5 g,3 times a day.Treatment group was given somatostatin,after dissolution with 5%glucose solution,250 mg were slowly injected intravenously first,and then 250 mg·h^-1 were immediately given intravenously,on the basis of control group.All patients were treated for 2 weeks.The levels of regulatory T cells(Tregs),inflammatory factors,SOD,MDA and degree of intestinal mucosa inflammation were compared before and after treatment.Results After treatment,the Tregs levels in treatment group and control group were(9.69±1.31)%,(6.89±1.23)%,the serum tumor necrosis factor-α(TNF-α)were(1.23±0.11),(1.98±0.24)ng·mL^-1,interleukin-6(IL-6)were(92.01±8.49),(116.09±11.24)ng·mL^-1,interleukin-8(IL-8)were(151.38±15.29),(219.63±18.17)ng·mL^-1,interleukin-10(IL^-10)were(71.18±9.64),(43.49±6.19)ng·mL^-1,SOD were(1.81±0.28),(1.31±0.21)U·mL^-1,MDA were(5.66±1.21),(6.81±1.41)nmol·mL^-1,all with significant difference(all P<0.05).After treatment,the proportion of level 0 patients in treatment group was higher than that in control group,and the proportion of levelⅡpatients was lower than that in control group(P<0.05).The total incidence of adverse drug reactions in treatment group amd control group were 7.94%,22.22%,with significant difference(P<0.05).Conclusion Somatostatin combined with mesalazine can significantly improve Tregs and inflammatory factors in UC patients,control inflammatory reaction of intesinal mucosa,reduce oxidative stress level,improve bowel function,and have a good therapeutic effect.
作者
张静
吴健媛
龚美巧
方炳强
马拥军
ZHANG Jing;WU Jian-yuan;GONG Mei-qiao;FANG Bing-qiang;MA Yong-jun(Department of Laboratory,Yiwu Central Hospital,Yiwu 322000,Zhejiang Province,China;Department of Neonatology,Yiwu Central Hospital,Yiwu 322000,Zhejiang Province,China;Department of Western Medicine,Yiwu Central Hospital,Yiwu 322000,Zhejiang Province,China;Department of Laboratory,Jinhua Central Hospital,Jinhua 321000,Zhejiang Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第18期2762-2764,2768,共4页
The Chinese Journal of Clinical Pharmacology
关键词
生长抑素
美沙拉嗪
溃疡性结肠炎
调节性T细胞
炎性因子
超氧化物歧化酶
丙二醛
肠黏膜炎症程度
somatostatin
mesalazine
ulcerative colitis
regulatory T cells
inflammatory factor
superoxide dismutase
malondialdehyde
degree of intestinal mucosa inflammation
